- Home
- MURA vs INAB Comparison
MURA vs INAB Comparison
Compare MURA & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- INAB
- Stock Information
- Founded
- MURA 2013
- INAB 2016
- Country
- MURA Ireland
- INAB United States
- Employees
- MURA N/A
- INAB N/A
- Industry
- MURA
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- INAB Health Care
- Exchange
- MURA Nasdaq
- INAB Nasdaq
- Market Cap
- MURA 45.8M
- INAB 14.5M
- IPO Year
- MURA N/A
- INAB 2021
- Fundamental
- Price
- MURA $2.62
- INAB $0.15
- Analyst Decision
- MURA Strong Buy
- INAB Strong Buy
- Analyst Count
- MURA 4
- INAB 2
- Target Price
- MURA $13.00
- INAB $3.60
- AVG Volume (30 Days)
- MURA 206.7K
- INAB 6.1M
- Earning Date
- MURA 05-14-2025
- INAB 05-07-2025
- Dividend Yield
- MURA N/A
- INAB N/A
- EPS Growth
- MURA N/A
- INAB N/A
- EPS
- MURA N/A
- INAB N/A
- Revenue
- MURA N/A
- INAB N/A
- Revenue This Year
- MURA $34.35
- INAB N/A
- Revenue Next Year
- MURA N/A
- INAB N/A
- P/E Ratio
- MURA N/A
- INAB N/A
- Revenue Growth
- MURA N/A
- INAB N/A
- 52 Week Low
- MURA $0.95
- INAB $0.11
- 52 Week High
- MURA $4.74
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- MURA 50.82
- INAB 46.63
- Support Level
- MURA $2.59
- INAB $0.13
- Resistance Level
- MURA $2.72
- INAB $0.19
- Average True Range (ATR)
- MURA 0.15
- INAB 0.02
- MACD
- MURA -0.02
- INAB 0.00
- Stochastic Oscillator
- MURA 29.41
- INAB 48.27
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.